TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15372361

Group type: EXPERIMENTAL
Intervention: Metformin (750 mg/day) for 6 months
Number of subjects: 16
Study: 11182010

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1500 microg/day
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microg/day
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 9347208

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms self-administered vaginally 3 days after methotrexate
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms self-administered vaginally 4 days after methotrexate
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms self-administered vaginally 5 days after methotrexate
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Complete abortion
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Failure rate
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Side effects of methotrexate
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Side effects of misoprostol
Number of subjects: 287
Study: 2285656

Group type: EXPERIMENTAL
Intervention: Ketanserin, 40 mg twice daily for 1 week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7029370

Group type: EXPERIMENTAL
Intervention: Relaxin and PGF2 alpha
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Relaxin and Estradiol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Estradiol and PGF2 alpha
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Relaxin, Estradiol, and PGF2 alpha
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Relaxin and PGF2 alpha (in larger study)
Number of subjects: 40
Study: 30642062

Group type: EXPERIMENTAL
Intervention: Taekwondo (TKD) intervention for one-and-a-half years
Number of subjects: 0
Study: 27834560

Group type: EXPERIMENTAL
Intervention: Very-heavy sled (80% body mass sled load)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (unresisted sprints)
Number of subjects: 16
Study: 24942813

Group type: EXPERIMENTAL
Intervention: Coping Power Program intervention
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study: 24559830

Group type: EXPERIMENTAL
Intervention: Cupping
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no cupping)
Number of subjects: 12
Study: 22660805

Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg biweekly (twice monthly)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg monthly (alternating with placebo)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 20403617

Group type: EXPERIMENTAL
Intervention: Nightly intraurethral alprostadil
Number of subjects: 139

Group type: COMPARATOR
Intervention: Sildenafil citrate (50 mg)
Number of subjects: 139
Study: 18832341

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (0.16 mJ/mm(2); 2000 impulses)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy
Number of subjects: 245
Study: 16027282

Group type: EXPERIMENTAL
Intervention: Radiation therapy with or without concurrent chemotherapy
Number of subjects: 36
Study: 11917241

Group type: EXPERIMENTAL
Intervention: Hydroxyurea in addition to stavudine (d4T) plus didanosine (ddI) and nevirapine (NVP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No hydroxyurea, receiving stavudine (d4T) plus didanosine (ddI) and nevirapine (NVP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 24

Group type: COMPARATOR
Intervention: No hydroxyurea
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (with and without hydroxyurea)
Number of subjects: 24
Study: 10750519

Group type: EXPERIMENTAL
Intervention: Active health education
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Passive health education
Number of subjects: 45

Group type: COMPARATOR
Intervention: No education
Number of subjects: 45
Study: 8624220

Group type: EXPERIMENTAL
Intervention: Citicoline 1000 mg/d for 3 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Citicoline 2000 mg/d for 2 months
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 1534249

Group type: EXPERIMENTAL
Intervention: Post-operative megavoltage radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 4030155

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 60

Group type: COMPARATOR
Intervention: EMG biofeedback
Number of subjects: 60
Study: 28964747

Group type: EXPERIMENTAL
Intervention: 4-hour fasting group
Number of subjects: 276

Group type: COMPARATOR
Intervention: 24-hour fasting group
Number of subjects: 276
Study: 26456813

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard supportive care
Number of subjects: 120
Study: 25038431

Group type: EXPERIMENTAL
Intervention: Mesalamine (1.2 g, 2.4 g, or 4.8 g) once daily for 104 weeks
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Placebo once daily for 104 weeks
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Mesalamine
Number of subjects: 1182
Study: 22853197

Group type: EXPERIMENTAL
Intervention: Nicotine patches (eight-week, step down program) dispensed at discharge
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Proactive telephone counseling provided by the state quitline after discharge
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Combined interventions (nicotine patches and telephone counseling)
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1640

Group type: COMPARATOR
Intervention: All interventions (patch alone, counseling alone, and combined interventions)
Number of subjects: 1640
Study: 19490744

Group type: EXPERIMENTAL
Intervention: Second-generation antidepressants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17377748

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.2 mg/ml applied to the osteotomy site for 30 min
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard EXT-DCR procedure (Control)
Number of subjects: 35
Study: 16014884

Group type: EXPERIMENTAL
Intervention: Single-chamber pacing (fixed-rate or rate-adaptive)
Number of subjects: 2021

Group type: COMPARATOR
Intervention: Dual-chamber pacing
Number of subjects: 2021

Group type: EXPERIMENTAL
Intervention: Single-chamber pacing
Number of subjects: 2021
Study: 12077687

Group type: EXPERIMENTAL
Intervention: 20 mg/d enalapril
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 9445316

Group type: EXPERIMENTAL
Intervention: Single dose of 250,000 IU intrapleural streptokinase (IPSK)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Serial doses of 250,000 IU intrapleural streptokinase (IPSK) every 12 hours for 3 days (total dose: 1.5 million IU)
Number of subjects: 16
Study: 8711268

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg per os 1 h before exercise
Number of subjects: 40
Study: 2315637

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide (Buscopan) 20 mg i.v.
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Glucagon 1 mg i.v.
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 7401741

Group type: EXPERIMENTAL
Intervention: Oxovinca; administered over three consecutive courses within a two-month period.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo; administered over three consecutive courses within a two-month period.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group; 10 normal individuals of comparable age.
Number of subjects: 33
Study: 31999182

Group type: EXPERIMENTAL
Intervention: Right-mild left hand preference trajectory
Number of subjects: 90

Group type: COMPARATOR
Intervention: Left-moderate right hand preference
Number of subjects: 90

Group type: COMPARATOR
Intervention: Right-moderate left hand preference
Number of subjects: 90
Study: 30332549

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE)
Number of subjects: 11
Study: 27477804

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) 1,200 mg plus glucosamine sulfate (GS) 1,500 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164

Group type: COMPARATOR
Intervention: Chondroitin sulfate (CS) plus glucosamine sulfate (GS) and Placebo
Number of subjects: 164
Study: 26055360

Group type: COMPARATOR
Intervention: RG7667 (1, 3, 5, and 10 mg/kg each antibody; single ascending dose)
Number of subjects: 181

Group type: COMPARATOR
Intervention: RG7667 (5 and 10 mg/kg each antibody monthly for 3 doses; multiple ascending dose)
Number of subjects: 181

Group type: COMPARATOR
Intervention: RG7667 (10 mg/kg each antibody monthly for 3 doses; multiple dose expansion)
Number of subjects: 181

Group type: COMPARATOR
Intervention: RG7667
Number of subjects: 181
Study: 23857311

Group type: EXPERIMENTAL
Intervention: Doxazosin (8 mg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21878207

Group type: EXPERIMENTAL
Intervention: 12-week progressive home-based program of moderate-intensity aerobic and resistance exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Attention control wait list group performing light stretching and flexibility exercises
Number of subjects: 24
Study: 19938905

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enclomiphene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Testosterone replacement
Number of subjects: 0
Study: 16728222

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5 to 40 mg)
Number of subjects: 3956

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 3956

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3956
Study: 15327032

Group type: EXPERIMENTAL
Intervention: MMP-9 levels in PP/TPMS
Number of subjects: 73

Group type: COMPARATOR
Intervention: MMP-9 levels in RRMS
Number of subjects: 73

Group type: COMPARATOR
Intervention: MMP-9 levels in healthy controls (HC)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Comparison of MMP-9 levels in PP/TPMS vs RRMS
Number of subjects: 73

Group type: COMPARATOR
Intervention: Comparison of MMP-9 levels in PP/TPMS vs HC
Number of subjects: 73
Study: 11318052

Group type: EXPERIMENTAL
Intervention: Acoustic mismatch with low memory load methodology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective recall task combined with low memory load methodology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attentional manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 9863080

Group type: EXPERIMENTAL
Intervention: Composite Divitriol Infusion (CDI)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study: 7945476

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) - transdermal estradiol (50 micrograms daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Calcium supplementation (400 mg daily)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) in patients taking steroids
Number of subjects: 200
Study: 3555580

Group type: EXPERIMENTAL
Intervention: 300 mg quinine bisulphate at night
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Serum quinine concentration
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Increased nightly dose of quinine
Number of subjects: 22
Study: 31232166

Group type: EXPERIMENTAL
Intervention: Activity and educational sessions delivered for six weeks during physical education class.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pedometer measurements taken during the intervention.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Data collection process for the intervention.
Number of subjects: 31
Study: 29505898

Group type: EXPERIMENTAL
Intervention: Eczema Care Plan (ECP)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 211
Study: 27071797

Group type: EXPERIMENTAL
Intervention: Higher levels of emotional well-being among adolescents who attended religious services but did not pray privately, feel God's presence, or identify as religious or spiritual.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highest overall religious/spiritual group.
Number of subjects: 0
Study: 24951828

Group type: EXPERIMENTAL
Intervention: Bivalent intramuscular norovirus virus-like particle vaccine (50 µg of each VLP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22058145

Group type: EXPERIMENTAL
Intervention: UDCA treatment
Number of subjects: 703

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Haplotype analysis
Number of subjects: 703
Study: 20572476

Group type: EXPERIMENTAL
Intervention: Navy Sexual Assault Intervention Training (SAIT) program
Number of subjects: 1505

Group type: COMPARATOR
Intervention: Educational video about HIV/AIDS (comparison condition)
Number of subjects: 1505
Study: 18192704

Group type: EXPERIMENTAL
Intervention: Oral calcitriol 0.75 mcg three times weekly for six weeks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Oral alfacalcidol 0.75 mcg three times weekly for six weeks
Number of subjects: 5
Study: 15983453

Group type: EXPERIMENTAL
Intervention: Liberal protocol group (LPG) - bolus of 10 ml/kg followed by 12 ml x kg(‐1) x h(‐1)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Restrictive protocol group (RPG) - 4 ml x kg(‐1) x h(‐1)
Number of subjects: 152
Study: 12028259

Group type: EXPERIMENTAL
Intervention: 50 microg oral cyanocobalamin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 10 microg oral cyanocobalamin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 10421886

Group type: EXPERIMENTAL
Intervention: Long-pulse dye laser (LPDL) with ALA (20% ALA emulsion, 585 nm, 18 J/cm²)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Incoherent light source with ALA (160 mW/cm², 60-160 J/cm²)
Number of subjects: 200

Group type: COMPARATOR
Intervention: LPDL without ALA (control group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: LPDL
Number of subjects: 200
Study: 7796066

Group type: EXPERIMENTAL
Intervention: Informational video added to the informed consent procedure for ECT
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual written document for informed consent
Number of subjects: 18
Study: 2028626

Group type: EXPERIMENTAL
Intervention: Actisomide 4.2 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Actisomide 8.4 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Actisomide 2.1 mg/kg
Number of subjects: 0
Study: 365798

Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 27471050

Group type: EXPERIMENTAL
Intervention: Comprehensive care programme (IG) including education from a respiratory nurse, physiotherapist support for pulmonary rehabilitation, 3-monthly telephone calls by a respiratory nurse for 1 year, and follow-up at a respiratory clinic with a respiratory specialist once every 3 months for 1 year.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Comprehensive care programme (IG)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care group (UG)
Number of subjects: 180
Study: 26130940

Group type: EXPERIMENTAL
Intervention: Herbal extract mouthwash
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate mouthwash
Number of subjects: 60
Study: 23278871

Group type: EXPERIMENTAL
Intervention: EO mouthrinse
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: FM mouthrinse
Number of subjects: 90

Group type: COMPARATOR
Intervention: Negative control (OHI alone)
Number of subjects: 90
Study: 21528592

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with rTMS
Number of subjects: 85

Group type: COMPARATOR
Intervention: Simple rTMS
Number of subjects: 85
Study: 19294472

Group type: EXPERIMENTAL
Intervention: Geriatrics home visit program (one home visit to practice geriatric assessment skills, reflective paper, small-group presentation)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Geriatrics home visit program
Number of subjects: 33
Study: 17459741

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 243

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 243

Group type: COMPARATOR
Intervention: Non-intervention (usual care)
Number of subjects: 243
Study: 14752194

Group type: EXPERIMENTAL
Intervention: Endovascular brachytherapy (n = 8 for PTA, n = 15 for PTA and stent)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo irradiation (n = 7 for PTA, n = 17 for PTA and stent)
Number of subjects: 47
Study: 11572538

Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham Therapeutic Touch
Number of subjects: 21
Study: 9780750

Group type: EXPERIMENTAL
Intervention: hGH (8 IU during the first five days after the intervention)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (conventional fluid therapy)
Number of subjects: 28
Study: 8166152

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg BID
Number of subjects: 105

Group type: COMPARATOR
Intervention: NPN (neomycin 250 mg QID, polymyxin‐B 100 mg QID, nalidixic acid 1,000 mg BID)
Number of subjects: 105
Study: 2980952

Group type: EXPERIMENTAL
Intervention: Fentanyl, 100 micrograms/kg (n = 16)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sufentanil, 15 micrograms/kg (n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 33
Study: 29572107

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% ophthalmic suspension
Number of subjects: 42

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 42
Study: 28028819

Group type: COMPARATOR
Intervention: Fresnel prisms
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Visual search training
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 87
Study: 26376650

Group type: EXPERIMENTAL
Intervention: Oral perhexiline for a median of 9 days
Number of subjects: 129
Study: 23159133

Group type: EXPERIMENTAL
Intervention: Colloid solution
Number of subjects: 237

Group type: COMPARATOR
Intervention: Crystalloid solution
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 237
Study: 21514555

Group type: EXPERIMENTAL
Intervention: Nugent score 9-10
Number of subjects: 535

Group type: COMPARATOR
Intervention: Normal flora
Number of subjects: 535
Study: 18287394

Group type: EXPERIMENTAL
Intervention: Sandblasted brackets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-sandblasted brackets
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall brackets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of control and experimental quadrants
Number of subjects: 60
Study: 18046927

Group type: EXPERIMENTAL
Intervention: Inhaled dry powder insulin (IDPI)
Number of subjects: 0
Study: 14723792

Group type: EXPERIMENTAL
Intervention: Active dissemination strategy based on The WHO Reproductive Health Library (RHL) including three interactive workshops over six months
Number of subjects: 40
Study: 11212627

Group type: EXPERIMENTAL
Intervention: Group decision making
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group size
Number of subjects: 0
Study: 9046141

Group type: EXPERIMENTAL
Intervention: Calcium alginate fibre swabs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple gauze swabs
Number of subjects: 0
Study: 7914104

Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine (2-CdA) administered as a single 120-hour continuous infusion (8.9 mg/m2 of body surface area per day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine (2-CdA)
Number of subjects: 22
Study: 3342158

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (no thrombolytic treatment)
Number of subjects: 150
Study: 30589098

Group type: EXPERIMENTAL
Intervention: Benidipine (8 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampin
Number of subjects: 0
Study: 27240265

Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy (CAT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Befriending (supportive treatment)
Number of subjects: 44
Study: 25365653

Group type: EXPERIMENTAL
Intervention: Topiramate (300 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24182325

Group type: EXPERIMENTAL
Intervention: Cetrorelix (5 mg/day on days 1 and 2; 3 mg/day on days 3-5)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cetrorelix
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 22702837

Group type: EXPERIMENTAL
Intervention: Clinical trial participation (n=142)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Non-participation (n=105)
Number of subjects: 247
Study: 19135375

Group type: EXPERIMENTAL
Intervention: Sub-vastus approach
Number of subjects: 231

Group type: COMPARATOR
Intervention: Medial parapatellar approach
Number of subjects: 231
Study: 17594733

Group type: COMPARATOR
Intervention: Aerosolized opioids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aerosolized furosemide
Number of subjects: 0
Study: 16354852

Group type: EXPERIMENTAL
Intervention: Interval exercise (IE) training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Constant-load exercise (CLE) training
Number of subjects: 19
Study: 12230022

Group type: EXPERIMENTAL
Intervention: TW970 (modified formula of chaihu-longu-muli-tang)
Number of subjects: 60
Study: 9667097

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Perceived barriers against the use of RCTs
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Evidence derived from RCTs
Number of subjects: 1
Study: 7993833

Group type: EXPERIMENTAL
Intervention: Preoperative combined chemotherapy (TMF regimen: thiotepa 20 mg, methotrexate 40 mg/m2, 5-fluorouracil 500 mg/m2) plus radiotherapy (Group I)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Preoperative radiation therapy only (Group II)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Preoperative combined chemotherapy plus radiotherapy (Group I)
Number of subjects: 271